Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study
- Registration Number
- NCT01815541
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Brief Summary
This is a biomedical research, prospective, mono centric, tolerance study Of the administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Patient over 18 years
- Inpatient orthopedic surgery
- Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci)
- Bacteria resistant to lincosamides, quinolones and rifampicin
- Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)
- Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL)
Read More
Exclusion Criteria
- Patient not affiliated to the social security
- Pregnant and lactating women
- Known hypersensitivity to teicoplanin (rash, ...)
- Patients with a central catheter or an implantable chamber
- Patient hemodialysis
- Patient has another participant biomedical research on a drug to prevent drug interactions
- Patient minor
- Patient major protected (protection of the court, wardship, trusteeship)
- Patient admitted for emergency or incapable of consent
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description teicoplanin teicoplanin this group receive the teicoplanin
- Primary Outcome Measures
Name Time Method measure of tolerance 6 weeks The frequencies of adverse reactions at the injection site SC will be measured to assess the local tolerance of teicoplanin by SC.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Amiens
🇫🇷Amiens, Picardie, France